June 10, 2020 / 8:46 PM / a month ago

BRIEF-Clovis Oncology Announces Completion Of Target Enrollment In The Athena Trial, A Phase 3 Maintenance Treatment Study In Front-Line, Newly-Diagnosed Advanced Ovarian Cancer

June 10 (Reuters) - Clovis Oncology Inc:

* CLOVIS ONCOLOGY ANNOUNCES COMPLETION OF TARGET ENROLLMENT IN THE ATHENA TRIAL, A PHASE 3 MAINTENANCE TREATMENT STUDY IN FRONT-LINE, NEWLY-DIAGNOSED ADVANCED OVARIAN CANCER

* CLOVIS ONCOLOGY INC - TOPLINE DATA FOR RUBRACA MONOTHERAPY ARM VERSUS PLACEBO EXPECTED 2H 2021

* CLOVIS ONCOLOGY - TOPLINE DATA FROM RUBRACA & OPDIVO IN COMBINATION VERSUS RUBRACA MONOTHERAPY EXPECTED ONE YEAR OR MORE LATER Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below